The first child to receive a new experimental gene therapy for a rare neurological disorder died a few days after dosing, the company sponsoring that trial said Wednesday.

The company, Capsida Biotherapeutics, is one of a group of companies and labs engineering new viruses potentially capable of safely ferrying genes deep into the brain. Its first effort was designed to treat STXBP1 encephalopathy, a condition that can cause seizures, developmental delays, and other symptoms.

The STXBP1 Foundation said in a note to community members that the company and investigators were still working to understand what happened.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page